UK markets closed

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
43.82+0.13 (+0.30%)
As of 12:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close43.69
Open43.62
Bid43.75 x 1200
Ask43.76 x 1300
Day's range43.46 - 43.88
52-week range37.80 - 46.97
Volume2,179,015
Avg. volume5,656,983
Market cap111.391B
Beta (5Y monthly)0.29
PE ratio (TTM)17.74
EPS (TTM)2.47
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield1.99 (4.55%)
Ex-dividend date19 May 2022
1y target est49.15
  • Zacks

    Gilead (GILD) Announces Positive Data on Hepcludex for HDV

    Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

  • Zacks

    GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

    GlaxoSmithKline (GSK) closed at $41.97 in the latest trading session, marking a +0.48% move from the prior day.

  • Motley Fool

    Buy the Dip on These 3 Healthcare Stocks

    With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Taylor Carmichael (Vir Biotechnology): Vir Bio is down about 45% in 2022, but it is one of my highest-confidence positions in healthcare right now. When the Food and Drug Administration gave Vir -- and its partner, GlaxoSmithKline -- an Emergency Use Authorization (EUA) for its COVID-19 treatment sotrovimab (trademark Xevudy), demand for the drug skyrocketed.